Previous Statements by MYL
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Mylan's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Pharmacy Benefit Managers (PBMs) 'operate within a sphere of secrecy,' Black Rock Pharmacy co-owner Brad Arthur told CNBC.
Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.